By using, you agree to our terms and use of cookies to enhance your experience.

ATTD publishes CGM recommendations

By Editor
9th January 2018
Clinical guidance

New consensus recommendations on use of continuous glucose monitoring (CGM) have been published.

They come from the Advanced Technologies & Treatments for Diabetes (ATTD) Congress and were published by Diabetes Care in an article called The International Consensus on Use of Continuous Glucose Monitoring.

The recommendations cover long-term glucose control, aiding clinical trials and improving risk assessment for diabetes-related complications.

An expert panel suggested hypoglycaemia represented a barrier to blood glucose control and provided appropriate recommendations.

The authors highlighted the need for education for people with diabetes interpret CGM data to improve control.

They concluded: “CGM is a robust research tool, and continuous glucose data should be recognized by governing bodies as a valuable and meaningful end point to be used in clinical trials of new drugs and devices for diabetes treatment.

“The identification of hypoglycaemia is as important as the measurement of time in range in clinical trials. Quantifying the duration and magnitude of glycaemic excursions provides another means of assessing glucose control. The unifying theme of trials investigating the usefulness of CGM technologies is that the device must be worn on a near-daily basis to optimize its benefits.

“The expert panel concludes that, in clinical practice, the advanced metrics of assessing continuous glucose data presented here are appropriate as outcome parameters that complement HbA1c for a wide range of patients with diabetes and should be considered for use to help them improve glycaemic control provided that appropriate educational and technical support is available.”

To view the recommendations, click here.

Comments (0)

Register an account or login to comment